Compare Medpace Holdings Inc (MEDP) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Under Armour Inc Class A — how do they compare? Medpace Holdings Inc trades at $598.87 (market cap $16.90B), while Under Armour Inc Class A trades at $5.22 (market cap $2.26B). The key difference: Medpace Holdings Inc is far larger — about 7.5× Under Armour Inc Class A's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| MEDP | UAA | |
|---|---|---|
Market Cap | $16.90B | $2.26B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $8.14 |
52-Week Low | $393.42 | $4.17 |
Enterprise Value | $16.52B | $3.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Under Armour (UAA) is trading at $5.245, down 10.49% today, reflecting ongoing challenges with revenue declines and negative profitability. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal a net loss of -$201.27M in 2025 and negative cash flow trends. Recent Q1 2027 earnings beat expectations but revealed weaker revenue and cautious guidance, with management maintaining profitability outlook despite sales headwinds.
The outlook remains challenging with declining revenues and negative margins, though current valuation metrics appear reasonable. Key risks include weak North American demand and competitive pressures, while potential catalysts include new product collaborations and cost management. Analyst consensus is mixed with 27% buy ratings but a $6.67 price target suggesting 27% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
